
Stefan Oschmann promoted to top job at Merck KGaA
pharmafile | October 13, 2015 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Merck KGaA, Stefan Oschmann
Merck KGaA has announced the promotion of its deputy chief executive, Stefan Oschmann, to the role of chief executive, starting April next year.
He will succeed Karl-Ludwig Kley, who is to retire after the company’s annual general meeting on April 29.
Oschmann, who will also assume the role of chairman of the executive board, was initially in charge of the company’s pharmaceutical business, before being appointed deputy chief executive at the beginning of this year.
Before joining Merck KGaA in 2011, German-born Oschmann was in charge of Merck & Co Inc’s emerging markets operations. The two companies share historic roots but have been under separate ownership since World War One.
Related Content

Exscientia enters AI drug discovery collaboration with Merck KGaA
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …

Merck KGaA’s cancer drug Bavencio gets EU approval
The EC has approved Merck KGaA’s BAVENCIO (avelumab) as monotherapy for the first-line maintenance treatment …

Company veteran Belén Garijo named as Merck KGaA’s first-ever female CEO
German pharma firm Merck KGaA has taken the decision to appoint its first female Chief …






